Dr. Azra Borogovac, MD

Dr. Borogovac practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Borogovac's NPI, 1164818639, was assigned on April 12, 2015. Dr. Borogovac graduated from UMass Chan Medical School in 2015. Dr. Borogovac holds California license A179647.

Dr. Borogovac's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Borogovac's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Borogovac to 1 more group practice or clinic and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Borogovac practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Borogovac's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Borogovac is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Borogovac's licenses on file in 3 states: California, Oklahoma and Massachusetts.

Dmand AI lists chronic anemia, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Borogovac treats.

CMS data shows 888 Medicare services from Dr. Borogovac across 4 procedure codes in 2024, for 154 Medicare patients. Medicare paid $77,287 for them. Every service was in an office.

CMS counts 154 Medicare patients who saw Dr. Borogovac in 2024. The largest group is 65 to 74, with 70 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 14% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Borogovac's median patient age at 69, with 51% women.

In 2024, Dr. Borogovac wrote 720 Medicare Part D claims for 77 patients. 73% of them were for generic drugs. CMS names the drug for 492 of them, across 22 drugs with 11 or more claims each, at $1,346,888 in total drug cost. In 2023, CMS named 204 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Borogovac for performance year 2024, reported as part of a group. Dr. Borogovac accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Borogovac as offering telehealth.

Dmand AI links 19 papers to Dr. Borogovac, published from 2009 to 2024. 2024 was the busiest year, with 4. The most frequent topics are Receptors, Chimeric Antigen, Immunotherapy, Adoptive and Immunotherapy. Dr. Borogovac has published most often in Semin Hematol. Dr. Borogovac's most frequent co-authors are Tanya Siddiqi, MD, Taha Mahdi Salih Al-Juhaishi, MD and Adam Asch, MD.

CMS Open Payments shows 47 general payments to Dr. Borogovac from 15 drug and device companies from 2018 to 2025. Speaker and faculty fees make up the largest share, 84% of the total. Janssen Pharmaceuticals, Inc paid the most, $17,070.

Dr. Borogovac graduated from UMass Chan Medical School in 2015.

Dr. Borogovac is in network with 10 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.